Your browser doesn't support javascript.
loading
The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
Khan, Aneal; Sirrs, Sandra M; Bichet, Daniel G; Morel, Chantal F; Tocoian, Adina; Lan, Lan; West, Michael L.
Afiliação
  • Khan A; Department of Pediatrics, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada.
  • Sirrs SM; Department of Medicine, Adult Metabolic Diseases Clinic, The University of British Columbia, Vancouver, BC, Canada.
  • Bichet DG; Department of Medicine, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montréal, QC, Canada.
  • Morel CF; Fred A. Litwin Family Centre for Clinical Genetics and Genomic Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Tocoian A; , Takeda, Lexington, MA, USA.
  • Lan L; , Takeda, Lexington, MA, USA.
  • West ML; Division of Nephrology, Department of Medicine, Dalhousie University, Rm 5090 ACC, QE II Health Sciences Centre, 5820 University Ave, Halifax, NS, B3H 1V8, Canada. mlwest@dal.ca.
Drugs R D ; 21(4): 385-397, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34542871
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Fabry / Alfa-Galactosidase Tipo de estudo: Clinical_trials / Guideline Limite: Animals / Child / Humans / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Fabry / Alfa-Galactosidase Tipo de estudo: Clinical_trials / Guideline Limite: Animals / Child / Humans / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article